| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
American Journal of Public Health, Vol 90, Issue 7 1100-1111, Copyright © 2000 by American Public Health Association
JOURNAL ARTICLE |
GS Zaric, PG Barnett and ML Brandeau
Cooperative Studies Program, Palo Alto Veterans Affairs Health Care System, Menlo Park, Calif. 94025, USA.
OBJECTIVES: This study determined the cost-effectiveness of expanding methadone maintenance treatment for heroin addiction, particularly its effect on the HIV epidemic. METHODS: We developed a dynamic epidemic model to study the effects of increased methadone maintenance capacity on health care costs and survival, measured as quality-adjusted life-years (QALYs). We considered communities with HIV prevalence among injection drug users of 5% and 40%. RESULTS: Additional methadone maintenance capacity costs $8200 per QALY gained in the high-prevalence community and $10,900 per QALY gained in the low-prevalence community. More than half of the benefits are gained by individuals who do not inject drugs. Even if the benefits realized by treated and untreated injection drug users are ignored, methadone maintenance expansion costs between $14,100 and $15,200 per QALY gained. Additional capacity remains cost-effective even if it is twice as expensive and half as effective as current methadone maintenance slots. CONCLUSIONS: Expansion of methadone maintenance is cost-effective on the basis of commonly accepted criteria for medical interventions. Barriers to methadone maintenance deny injection drug users access to a cost-effective intervention that generates significant health benefits for the general population.
This article has been cited by other articles:
|
|
 |
|
  I. Popovici, M. T. French, and J. R. McKay Economic Evaluation of Continuing Care Interventions in the Treatment of Substance Abuse: Recommendations for Future Research Eval Rev, December 1, 2008; 32(6): 547 - 568. [Abstract] [PDF]
|
|
|
|
 |
|
 A. M. Bayoumi MD MSc and G. S. Zaric PhD The cost-effectiveness of Vancouver's supervised injection facility Can. Med. Assoc. J., November 18, 2008; 179(11): 1143 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Werb, T. Kerr, W. Small, K. Li, J. Montaner, and E. Wood HIV risks associated with incarceration among injection drug users: implications for prison-based public health strategies J. Public Health Med., June 1, 2008; 30(2): 126 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Zaric, A. M. Bayoumi, M. L. Brandeau, and D. K. Owens The Cost-Effectiveness of Counseling Strategies to Improve Adherence to Highly Active Antiretroviral Therapy among Men Who Have Sex with Men Med Decis Making, June 1, 2008; 28(3): 359 - 376. [Abstract] [PDF]
|
|
|
|
|
|
J. Hornberger, M. Holodniy, K. Robertus, M. Winnike, E. Gibson, and E. Verhulst A Systematic Review of Cost-Utility Analyses in HIV/AIDS: Implications for Public Policy Med Decis Making, December 1, 2007; 27(6): 789 - 821. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Schilling, K. Dornig, and L. Lungren Treatment of Heroin Dependence: Effectiveness, Costs, and Benefits of Methadone Maintenance Research on Social Work Practice, January 1, 2006; 16(1): 48 - 56. [Abstract] [PDF]
|
|
|
|
 |
|
 B. J. Turner, C. Laine, Y.-t. Lin, and K. Lynch Barriers and Facilitators to Primary Care or Human Immunodeficiency Virus Clinics Providing Methadone or Buprenorphine for the Management of Opioid Dependence Arch Intern Med, August 8, 2005; 165(15): 1769 - 1776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Howell, R. B. Greifinger, and A. S. Sommers What Is Known About the Cost-Effectiveness of Health Services for Returning Prisoners? Journal of Correctional Health Care, April 1, 2004; 10(3): 399 - 436. [Abstract] [PDF]
|
|
|
|
|
|
M. J. Krantz and P. S. Mehler Treating Opioid Dependence: Growing Implications for Primary Care Arch Intern Med, February 9, 2004; 164(3): 277 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Clark High dose buprenorphine may be an effective interim treatment for long term heroin users waiting for drug-assisted rehabilitation Evid. Based Ment. Health, February 1, 2003; 6(1): 30 - 30. [Full Text] [PDF]
|
|
|
|
|
|
F. C. Kuehne, U. Bethe, K. Freedberg, and S. J. Goldie Treatment for Hepatitis C Virus in Human Immunodeficiency Virus-Infected Patients: Clinical Benefits and Cost-effectiveness Arch Intern Med, December 9, 2002; 162(22): 2545 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Nelson, N. Galai, M. Safaeian, S. A. Strathdee, D. D. Celentano, and D. Vlahov Temporal Trends in the Incidence of Human Immunodeficiency Virus Infection and Risk Behavior among Injection Drug Users in Baltimore, Maryland, 1988-1998 Am. J. Epidemiol., October 1, 2002; 156(7): 641 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Pollack The Challenge and Future of HIV Prevention Journal of Health Politics Policy and Law, February 1, 2002; 27(1): 111 - 121. [PDF]
|
|
|
|
 |
|
 C. Laine, W. W. Hauck, M. N. Gourevitch, J. Rothman, A. Cohen, and B. J. Turner Regular Outpatient Medical and Drug Abuse Care and Subsequent Hospitalization of Persons Who Use Illicit Drugs JAMA, May 9, 2001; 285(18): 2355 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. O'Connor Treating Opioid Dependence -- New Data and New Opportunities N. Engl. J. Med., November 2, 2000; 343(18): 1332 - 1334. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
